We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

ANOSMIA MARKET ANALYSIS

Anosmia Market, by Type (Idiopathic Anosmia and Congenital Anosmia), by Treatment (Therapies (Nasal Endoscopy and Imaging) and Medications (Decongestants, Antihistamines, and Steroid Nasal Sprays)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

  • Published In : Dec 2020
  • Code : CMI4334
  • Pages :140
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Anosmia, a smell blindness, is the loss of the ability to smell. Anosmia may be temporary or permanent. Anosmia is regarded as a rare condition, but probably more common than many people think.  According to the Fifth Sense, U.K., in 2020, various studies and survey performed in number of countries suggests that prevalence of smell loss worldwide is 0.1% to over 5%.

Global Anosmia Market – Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic is expected to hamper the global anosmia market growth during the forecast period. The COVID-19 pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector has been impacted majorly due to the COVID-19 pandemic. The shutdown has disrupted the supply, distribution, and manufacture of medical supplies globally.

Furthermore, the coronavirus pandemic has hampered the development, clinical trials, production, and supply of drugs and other healthcare products and also have affected growth of the healthcare businesses of various companies across the globe. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. As a result, the impact of the COVID-19 pandemic is expected to limit growth of the market during the forecast period.

The global anosmia market is estimated to be valued at US$ 2,500.7 million in 2020 and is expected to exhibit a CAGR of 6.7% during the forecast period (2020-2027).

Figure 1: Global Anosmia Market Share (%) Analysis, By Type, 2020

ANOSMIA MARKET

To learn more about this report, Request sample copy

Increasing incidence of anosmia is expected to drive growth of the global anosmia market during the forecast period.

Rising anosmia cases is expected to drive the anosmia market growth over the forecast period. For instance, according to an article published by the ENT UK at The Royal College of Surgeons of England in 2020, reports that novel COVID-19 virus causes anosmia in infected patients.

Moreover, the same source, ENT UK at The Royal College of Surgeons of England in 2020, also reports that 30% of patients in South Korea, had anosmia. Similarly, according to the same source in Germany it is reported that more than 2 in 3 confirmed cases have anosmia.

Anosmia Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 2,500.7 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.7% 2027 Value Projection: US$ 3,950.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Idiopathic Anosmia, Congenital Anosmia.
  • By Treatment:
    • Therapies: Nasal Endoscopy, Imaging.
    • Medications: Decongestants, Antihistamines, Steroid Nasal Sprays.
Companies covered:

Mylan N.V., Pfizer Inc., Atom Pharma, RANBAXY LABORATORIES LIMITED, Alde Medi Impex, GlaxoSmithkline plc, Sandoz (Novasrtis AG), Inke S.A., Taj Pharmaceuticals Limited, and Sanofi

Growth Drivers:
  • Increasing number of anosmia cases
  • Rising research grants and research activities for drug development for anosmia
Restraints & Challenges:
  • Lack of approved drugs or therapeutics for anosmia

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Global Anosmia Market – Restraints

Lack of approved drugs or therapeutics for the anosmia is the major factor that is expected to hinder the market growth. Currently, decongestants, antihistamines, and steroid nasal sprays are used off label for the treatment of the anosmia. 

Global Anosmia Market – Regional Analysis

On the basis of region, the global anosmia market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to dominate the global anosmia market during the forecast period, owing to increasing anosmia cases in the region. For instance, according to an article published by the National Center for Biotechnology Information (NCBI) in 2017, reports that anosmia affects 3.2% (3.4 million people) of U.S. adults, who are aged above 40 years.    

Figure 2: Global Anosmia Market Value (US$ Mn), by Region, 2020

ANOSMIA MARKET

To learn more about this report, Request sample copy

Global Anosmia Market - Competitive Landscape

Some of the key players operating in the global anosmia market include Mylan N.V., Pfizer Inc., Atom Pharma, RANBAXY LABORATORIES LIMITED, Alde Medi Impex, GlaxoSmithkline plc, Sandoz (Novasrtis AG), Inke S.A., Taj Pharmaceuticals Limited, and Sanofi, amongst others.

Share

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The global Anosmia Market size was valued at USD 2,500.7 million in 2020 and is expected to reach USD 3,950.3 million in 2027.

The global anosmia market is expected to exhibit a CAGR of 6.7% during the forecast period (2020-2027).

The value of the global anosmia market is estimated to be valued at US$ 2,500.7 million in 2020.

Mylan N.V., Pfizer Inc., Atom Pharma, RANBAXY LABORATORIES LIMITED, Alde Medi Impex, GlaxoSmithkline plc, Sandoz (Novasrtis AG), Inke S.A., Taj Pharmaceuticals Limited, and Sanofi are some of the prominent players operating in the global anosmia market.

The global anosmia market is expected to be valued at US$ 3,950.3 million in 2027.

North America is the prominent region in the global anosmia market.

Increasing number of anosmia cases and rising research grants and research activities for drug development for anosmia by the market players are some of the key factors driving the global anosmia market growth.
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type





Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.